The prestigious scientific journal The Lancet publishes the clinical results of the Abdala vaccine.

The prestigious British journal The Lancet Regional Health-Americas published a scientific article on the results of phase 3 clinical trials of the Cuban vaccine Abdala (Center for Genetic Engineering and Biotechnology).

The publication states that the trial demonstrated the safety, tolerability and efficacy of the vaccine at 92.28% against symptomatic disease caused by COVID-19 and 92.88% against moderate/severe forms of the disease. There were no critical patients or deaths in the Abdala vaccine group.

The study was conducted in 18 clinical centers in the provinces of Santiago de Cuba, Guantanamo and Granma, with 48,290 volunteers aged 19 to 80 years.

These results led to the approval of Abdala for emergency use and its use in mass vaccinations, which had a direct impact on the control of the pandemic among the Cuban population.

The article (Evaluation of randomized, double-blind, placebo-controlled clinical trials of the efficacy and safety of the SARS-CoV-2 recombinant RBD spike protein vaccine in adults. ABDALA-3 study) emphasizes that the Abdala vaccine was safe, well tolerated and highly effective, and fit the target profile. WHO product for COVID-19 vaccines.

“These results, along with the immunization schedule and the advantage of simple storage and handling conditions at 2-8°C, make this vaccine an option for use in immunization strategies as a key tool to fight the pandemic.”

Source: Juventud Rebelde


Please enter your comment!
Please enter your name here

Read More